Veledimex
- Generic Name
- Veledimex
- Drug Type
- Small Molecule
- Chemical Formula
- C27H38N2O3
- CAS Number
- 1093130-72-3
- Unique Ingredient Identifier
- ASU841TV0X
- Background
Veledimex has been used in trials studying the treatment of Glioblastoma Multiforme, Metastatic Breast Cancer, and Anaplastic Oligoastrocytoma.
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT04006119
- Locations
- 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
- Conditions
- SclerodermaMorpheaScleroderma, Localized
- Interventions
- Genetic: FCX-013
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 1
- Registration Number
- NCT03740724
- Locations
- 🇺🇸
Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03679754
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸NYU - Langone Health, New York, New York, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT03636477
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Biological: Ad-RTS-hIL-12
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT02423902
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
- Conditions
- Glioblastoma MultiformeAnaplastic Oligoastrocytoma
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT02026271
- Locations
- 🇺🇸
Cedars-Sinai, Los Angeles, California, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
🇺🇸Northwestern, Chicago, Illinois, United States
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT01397708
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸The Angeles Clinic, Los Angeles, California, United States
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT00815607
- Locations
- 🇺🇸
Goshen Clinic, Goshen, Indiana, United States
🇺🇸Billings Clinic, Billings, Montana, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.